Life-changing therapies to help people build families and live better lives
At Ferring, we are committed to helping people build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in more than 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.
News
-
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
-Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3 AEs, there were no Grade 4 or 5 AEs — and no new safety si...
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
-Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity o...
-
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
-Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies to evaluate ADSTILADRIN demonstrate Ferring’s commitment to...